HAIFA, Israel I April 11, 2013 I Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem’s PLX-PAD cells for PAH.
PAH is characterized by abnormally high blood pressure in the arteries of the lungs and leads to an increased workload on the right side of the heart.
United Therapeutics plans to conduct a single center, open-label, dose-escalation study in patients diagnosed with PAH. The study will enroll up to nine patients in three dosing levels with PLX-PAD cells administered intravenously (IV). The primary endpoint of the study is to evaluate the safety of PLX-PAD cells in a follow-up period of one year. Secondary efficacy endpoints at six weeks post-treatment are designed to assess cardio-respiratory function and include six-minute walk distance, cardiac hemodynamic parameters via a right heart catheterization and echocardiogram and pulmonary metabolism via a positron emission tomography (PET) scan.
Zami Aberman, Chairman and Chief Executive Officer of Pluristem Therapeutics stated, “We are very pleased with the progress of the project, moving our partnership with United Therapeutics to the next step. The in-vitro and pre-clinical development studies demonstrated that the administration of PLX-PAD cells appears to be safe and potentially effective in animal models of PAH. We are now looking forward to receiving clinical data from this trial in evaluating the safety of our PLX-PAD cell in treating PAH patients.”
Under the terms of Pluristem’s licensing agreement with United Therapeutics Corporation, United Therapeutics made an upfront payment of $7 million to Pluristem. Pluristem is also eligible to receive regulatory milestone and other payments totaling up to an additional $48 million with United Therapeutics bearing all the costs of conducting all of the clinical trials for the indication of PAH. The licensing agreement also provides that, following commercialization, United Therapeutics will purchase the PLX-PAD cell product from Pluristem at a specified margin over Pluristem’s cost. In addition, United Therapeutics will pay Pluristem specified royalties as a percentage of its gross profits generated from the sale of the PLX-PAD cell developed product.
Preclinical studies to evaluate the hemodynamic effects from the IV administration of PLX-PAD cells in the monocrotaline (MCT) rat model of PAH have been performed. These studies demonstrated that PLX-PAD cell treatment can lead to improvements in right ventricular systolic pressure (RVSP) compared to placebo-treated animals. Some treatment groups also demonstrated an improvement in right ventricular hypertrophy (RVH) as compared to placebo-treated animals.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening diseases.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.
Pluristem has a strong patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
SOURCE: United Therapeutics
Post Views: 142
HAIFA, Israel I April 11, 2013 I Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem’s PLX-PAD cells for PAH.
PAH is characterized by abnormally high blood pressure in the arteries of the lungs and leads to an increased workload on the right side of the heart.
United Therapeutics plans to conduct a single center, open-label, dose-escalation study in patients diagnosed with PAH. The study will enroll up to nine patients in three dosing levels with PLX-PAD cells administered intravenously (IV). The primary endpoint of the study is to evaluate the safety of PLX-PAD cells in a follow-up period of one year. Secondary efficacy endpoints at six weeks post-treatment are designed to assess cardio-respiratory function and include six-minute walk distance, cardiac hemodynamic parameters via a right heart catheterization and echocardiogram and pulmonary metabolism via a positron emission tomography (PET) scan.
Zami Aberman, Chairman and Chief Executive Officer of Pluristem Therapeutics stated, “We are very pleased with the progress of the project, moving our partnership with United Therapeutics to the next step. The in-vitro and pre-clinical development studies demonstrated that the administration of PLX-PAD cells appears to be safe and potentially effective in animal models of PAH. We are now looking forward to receiving clinical data from this trial in evaluating the safety of our PLX-PAD cell in treating PAH patients.”
Under the terms of Pluristem’s licensing agreement with United Therapeutics Corporation, United Therapeutics made an upfront payment of $7 million to Pluristem. Pluristem is also eligible to receive regulatory milestone and other payments totaling up to an additional $48 million with United Therapeutics bearing all the costs of conducting all of the clinical trials for the indication of PAH. The licensing agreement also provides that, following commercialization, United Therapeutics will purchase the PLX-PAD cell product from Pluristem at a specified margin over Pluristem’s cost. In addition, United Therapeutics will pay Pluristem specified royalties as a percentage of its gross profits generated from the sale of the PLX-PAD cell developed product.
Preclinical studies to evaluate the hemodynamic effects from the IV administration of PLX-PAD cells in the monocrotaline (MCT) rat model of PAH have been performed. These studies demonstrated that PLX-PAD cell treatment can lead to improvements in right ventricular systolic pressure (RVSP) compared to placebo-treated animals. Some treatment groups also demonstrated an improvement in right ventricular hypertrophy (RVH) as compared to placebo-treated animals.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening diseases.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.
Pluristem has a strong patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
SOURCE: United Therapeutics
Post Views: 142
